S SUPERNUS PHARMACEUTICALS INC
| Market Cap | $2.91B |
| P/E Ratio | — |
| Forward P/E | 11.96 |
| Dividend Yield | — |
| Beta | 0.73 |
| 52W Range | $30.29 - $57.00 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Third Avenue Management Third Avenue Management | 1.71% | $9.42M | 189,493 | — |
Insider Trading
| Insider Name of the company insider who made the trade 24 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 412 | $50.48 | $20.80K | 18 Mar 2026 | 16 Mar 2026 |
| Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 6,838 | $49.55 | $338.82K | 18 Mar 2026 | 16 Mar 2026 |
| Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 22,290 | $50.73 | $1.13M | 17 Mar 2026 | 16 Mar 2026 |
| Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 27,710 | $49.95 | $1.38M | 17 Mar 2026 | 16 Mar 2026 |
| Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 15,886 | $50.49 | $802.08K | 16 Mar 2026 | 16 Mar 2026 |
| Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 34,114 | $50.18 | $1.71M | 16 Mar 2026 | 16 Mar 2026 |
| Khattar Jack A.President, CEO | Sale | 120 | $51.75 | $6.21K | 13 Mar 2026 | 13 Mar 2026 |
| Khattar Jack A.President, CEO | Sale | 10,742 | $51.00 | $547.84K | 13 Mar 2026 | 13 Mar 2026 |
| Khattar Jack A.President, CEO | Sale | 24,138 | $50.09 | $1.21M | 13 Mar 2026 | 13 Mar 2026 |
| Hudson Frederick M. | Sale | 5,369 | $50.61 | $271.73K | 12 Mar 2026 | 12 Mar 2026 |
| Horich William ToddSVP, Commercial Operations | Sale | 4,439 | $55.00 | $244.15K | 10 Mar 2026 | 06 Mar 2026 |
| Mottola FrankSVP, Chief Tech. Ops. Officer | Sale | 1,623 | $53.65 | $87.07K | 09 Mar 2026 | 06 Mar 2026 |
| Horich William ToddSVP, Commercial Operations | Sale | 4,438 | $54.00 | $239.65K | 09 Mar 2026 | 06 Mar 2026 |
| GEMAYEL GEORGES | Sale | 8,787 | $53.00 | $465.71K | 06 Mar 2026 | 05 Mar 2026 |
| GEMAYEL GEORGES | Sale | 10,000 | $53.71 | $537.10K | 05 Mar 2026 | 05 Mar 2026 |
| Sensenig Bethany | Sale | 1,217 | $50.31 | $61.23K | 19 Feb 2026 | 23 Feb 2026 |
| Sensenig Bethany | Sale | 3,258 | $51.27 | $167.04K | 19 Feb 2026 | 23 Feb 2026 |
| Mottola FrankSVP, Chief Tech. Ops. Officer | Sale | 15,000 | $50.47 | $757.05K | 19 Dec 2025 | 22 Dec 2025 |
| Mottola FrankSVP, Chief Tech. Ops. Officer | Sale | 5,000 | $50.22 | $251.10K | 19 Dec 2025 | 22 Dec 2025 |
| Bhatt Padmanabh P.Sr. VP of IP, CSO | Sale | 710 | $44.44 | $31.55K | 18 Dec 2025 | 19 Dec 2025 |
| NEWHALL CHARLES W III | Sale | 1,200 | $51.55 | $61.86K | 09 Oct 2025 | 10 Oct 2025 |
| NEWHALL CHARLES W III | Sale | 23,800 | $50.73 | $1.21M | 09 Oct 2025 | 10 Oct 2025 |
| Khattar Jack A.President, CEO | Sale | 1,529 | $51.46 | $78.68K | 09 Oct 2025 | 10 Oct 2025 |
| Khattar Jack A.President, CEO | Sale | 58,371 | $50.55 | $2.95M | 09 Oct 2025 | 10 Oct 2025 |
Frequently Asked Questions
What is SUPN stock price today?
SUPERNUS PHARMACEUTICALS INC (SUPN) is currently trading at $50.48. The stock has a 52-week range of $30.29 to $57.00 and a market capitalization of $2.91B.
Is SUPN a good stock to buy in 2026?
SUPERNUS PHARMACEUTICALS INC has a P/E ratio of N/A (forward P/E: 12.0), a dividend yield of none, and 1-year performance of +55.4%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling SUPN stock?
There have been 24 insider transactions for SUPN in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has SUPN stock performed over the past year?
SUPERNUS PHARMACEUTICALS INC (SUPN) has returned +55.4% over the past 12 months. The stock traded between $30.29 and $57.00 during this period, and is currently at $50.48.
Which hedge funds own SUPN (SUPERNUS PHARMACEUTICALS INC)?
1 tracked hedge funds currently hold SUPN in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is SUPN's market cap and valuation?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a market capitalization of $2.91B. The trailing P/E ratio is N/A and forward P/E is 12.0. The stock is classified in the Healthcare sector.
What is SUPN's revenue and profitability?
SUPERNUS PHARMACEUTICALS INC reported revenue of $718.95M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.73.
What sector is SUPN in and who are its biggest institutional holders?
SUPERNUS PHARMACEUTICALS INC (SUPN) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.